Gilead Sciences | GILD - Cost Of Sales



Gilead Sciences reported $1.5B in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
AbbVie USD 4.35B 344M Jun/2025
Agios Pharmaceuticals USD 1.7M 617K Jun/2025
ALKERMES USD 49.46M 263K Jun/2025
Alnylam Pharmaceuticals USD 142.95M 71.91M Jun/2025
Amgen USD 3.01B 406M Jun/2025
Biogen USD 605M 24.3M Jun/2025
BioMarin Pharmaceutical USD 154.94M 3.38M Jun/2025
Bristol-Myers Squibb USD 3.37B 339M Jun/2025
Eli Lilly USD 2.45B 223.6M Jun/2025
Gilead Sciences USD 1.5B 39M Jun/2025
GlaxoSmithKline GBP 2.16B 241M Jun/2025
Glaxosmithkline GBP 2.16B 363M Jun/2025
Incyte USD 78.77M 10.96M Jun/2025
J&J USD 7.6B 304M Jun/2025
Merck USD 2.82B 53M Jun/2025
Moderna USD 119M 29M Jun/2025
Neurocrine Biosciences USD 11.3M 2.1M Jun/2025
Novartis USD 3.32B 95M Jun/2025
Pfizer USD 4.99B 2.4B Jun/2025
PTC Therapeutics USD 15.48M 2.62M Jun/2025
Regeneron Pharmaceuticals USD 530.2M 264.7M Jun/2025
Sanofi EUR 2.99B 103M Jun/2025
Sarepta Therapeutics USD 153.22M 15.66M Jun/2025
United Therapeutics USD 175.2M 102.3M Jun/2025
Vertex Pharmaceuticals USD 407.5M 44.5M Jun/2025